Overview
AARD market data
Price History
AARD price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.93 Diluted earnings per share over the trailing twelve months.
- Beta
- 4.01 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.35 – $17.94 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $141.8 · P/B 2.68.
Company news
HC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price TargetBenzinga · Jul 20, 2026, 11:20 AM
B. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7Benzinga · May 15, 2026, 5:03 PM
This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For FridayBenzinga · May 15, 2026, 3:49 PM
BTIG Downgrades Aardvark Therapeutics to NeutralBenzinga · May 15, 2026, 2:50 PM
FDA Halts Aardvark Therapeutics Rare Disease StudyBenzinga · May 15, 2026, 2:30 PM
This BWX Technologies Analyst Turns Bullish; Here Are Top 3 Upgrades For FridayBenzinga · May 15, 2026, 1:00 PM
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For FridayBenzinga · May 15, 2026, 12:30 PM
Morgan Stanley Downgrades Aardvark Therapeutics to Underweight, Lowers Price Target to $3Benzinga · May 15, 2026, 11:00 AM
Aardvark Therapeutics Says FDA Places Full Clinical Hold On Its Investigational New Drug Application For ARD-101 Related To Prior Announced Voluntary PauseBenzinga · May 14, 2026, 8:04 PM
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens BermanGlobenewswire Inc · May 14, 2026, 7:15 PM